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Background: Exportin 1 (XPO1), also called chromosome region maintenance 1 (CRM1), is the sole exportin
mediating transport of many multiple tumor suppressor proteins out of the nucleus.
Aim and methods: To verify the hypothesis that XPO1 inhibition affects prostate cancer (PCa) metastatic potential,
orally available, potent and selective, SINE compounds, Selinexor (KPT- 330) and KPT-251, were tested in preclinical
models known to generate bone lesions and systemic tumor spread.
Results: In vitro, Selinexor reduced both secretion of proteases and ability to migrate and invade of PCa cells.
SINEs impaired secretion of pro-angiogenic and pro-osteolytic cytokines and reduced osteoclastogenesis in
RAW264.7 cells. In the intra-prostatic growth model, Selinexor reduced DU145 tumor growth by 41% and 61% at
the doses of 4 mg/Kg qd/5 days and 10 mg/Kg q2dx3 weeks, respectively, as well as the incidence of macroscopic
visceral metastases. In a systemic metastasis model, following intracardiac injection of PCb2 cells, 80% (8/10) of
controls, 10% (1/10) Selinexor- and 20% (2/10) KPT-251-treated animals developed radiographic evidence of lytic
bone lesions. Similarly, after intra-tibial injection, the lytic areas were higher in controls than in Selinexor and
KPT-251 groups. Analogously, the serum levels of osteoclast markers (mTRAP and type I collagen fragment, CTX),
were significantly higher in controls than in Selinexor- and KPT-251-treated animals. Importantly, overall survival and
disease-free survival were significantly higher in Selinexor- and KPT-251-treated animals when compared to controls.
Conclusions: Selective blockade of XPO1-dependent nuclear export represents a completely novel approach for
the treatment of advanced and metastatic PCa.
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Prostate cancer (PCa) is the second leading type of
cancer in men in european countries [1]. Deregulation of
cell proliferation associated with bypassing of apoptosis,
resistance to hormonal control and metastasis are all
essential elements in the PCa progression. When confined
to the prostate, PCa is effectively treated by surgery or* Correspondence: claudio.festuccia@univaq.it
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unless otherwise stated.radiotherapy. For patients with PCa that has escaped the
prostate, the primary modality is to treat with androgen
ablation therapy. Androgen ablation therapy provides
variable periods of disease remission, but is not curative.
Eventually, nearly all PCa becomes refractory to androgen
deprivation and metastasizes to bone, leading to painfully
debilitating fractures, spinal compression and rapid de-
cline [2]. In addition, androgen deprivation resistant PCa
bone metastases are usually resistant to standard therapies
including radiation and chemotherapy. The major cha-
racteristic of PCa cancer bone metastases is that theyl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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lytic bone lesions that are not as efficiently treated with
the osteoclast inhibitors [3-6]. Treatments that target
the bone microenvironment such as bisphosphonates
including zolendronic acid [4] and the RANKL inhibitor,
denosumab [5], which inhibits osteoclasts and associated
osteolysis, have been effective in delaying the onset of
skeletal related events (SREs) in some cancers, but mixed
results in PCa. Novel therapeutic modalities that prevent
and treat PCa associated SREs are needed.
Transport of macromolecules across the nuclear
membrane is fundamental to the proper functioning of a
living cell. For example, the ability to localize to the nu-
cleus is essential for transcription factor activation, and
spatial separation of proteins is commonly used as a
mechanism for preventing spontaneous signal activa-
tion. XPO1/CRM1 (Exportin 1 or Chromosome Region
Maintenance 1 protein) is one of seven mammalian
export proteins that facilitates the transport of large
macromolecules including RNAs and proteins across
the nuclear membrane to the cytoplasm [7-10]. In ad-
dition to nuclear-cytosolic transport, XPO1 also plays a
role in centrosome duplication and spindle assembly,
especially in response to DNA damage [11]. Many cargo
proteins that depend exclusively on XPO1 for nuclear
export function as tumor suppressor proteins including
p53, BRCA1, Survivin, NPM, APC, FOXO, and others,
regulating cell growth and apoptosis [12-16]. An imbal-
ance in the cytosolic level of these proteins has been
observed in cancer cells, resulting in inactivation of tumor
suppressor functions. Thus, the concept of inhibiting
XPO1 has been explored as a potential therapeutic inter-
vention in several tumors [17-22], but not in PCa. Because
XPO1 inhibition impacts multiple anti-tumor and growth
suppressive signaling pathways, it may impact PCa in-
cluding those that have become androgen independent.
A well-known natural product XPO1-specific inhibitor,
Leptomycin, LMB, possesses strong anti-tumor activity
in vitro, but phase I trials of LMB were discontinued
because of its toxicity and lack of apparent efficacy in
the tolerable dose range. Mutka et al. [23] noted that
LMB has off-target effects against proteins other than
XPO1, and that derivitization of LMB can ameliorate
many of the side effects of LMB in mice, indicating that
LMB’s off-target effects contribute to toxicities. The
finding that inhibition of XPO1 itself was not the cause
of LMB’s toxicity is promising in terms of the develop-
ment of anticancer drugs targeting XPO1. In order to
efficiently discover novel small-molecule, drug-like, se-
lective inhibitors of nuclear export (SINE) that block
XPO1-dependent nuclear export, we applied a virtual
screening workflow based on a combination of protein
modeling and simulations, physicochemical filters, and
high-throughput molecular docking [23,24]. SINEs aresmall molecule, drug-like compounds that form a slowly
reversible covalent bond with Cys528 in the cargo-NES
binding domain of XPO1 [17,25]. These SINE compounds
are active in a number of hematologic and solid tumor
xenograft models. One of these compounds, Selinexor
(KPT-330), which shows potent and selective inhibition of
XPO1 and has good oral bioavailability in animals [25-27],
has entered phase 1 studies in patients with advanced
solid tumors (clinicaltrials.gov:NCT01607905). The objec-
tive of our study was to test the hypothesis that XPO1
inhibition affects the metastatic potential of PCa cells
using one model of intraprostatic tumor growth and two
models of bone metastasis.Materials and methods
Materials
All the materials for tissue culture were purchased from
Hyclone (Cramlington, NE, USA). Plasticware was obtained
from Nunc (Roskilde, Denmark). P27 (C19, sc-528), CRM1
(H300, sc-5595), FAK (C-903, sc-932), β-actin (sc-130065)
and Lamin B (C-20, sc-6216) were purchased from Santa-
Cruz Botechnology Inc (Heidelberg, Germany). ELAV1/
HuR1 antibody was purchased from Aviva systems biology
Corporation (San Diego, CA, USA). KPT-251 and Selinexor
(KPT-330) are two structurally similar, selective XPO1 inhi-
bitors with distinct pharmacokinetic (PK) properties were
provided by Karyopharm Therapeutics Inc. (Natick, MA)
[21,23]. Alendronate (Ale) and poly (2-hydroxyethyl
methacrylate) (poly-HEMA) were purchased from Sigma-
Aldrich (St Louis, MA).Cell lines
Androgen independent PC3 and DU145 cell lines were
obtained from ATCC (LGC standards, Teddington, UK).
Bioware Ultra Cell line, PC3M-pro4-luc cells were kindly
provided from G. van der Pluijm (Uro-Oncology Research
Laboratory, Leiden, The Netherlands PC-3 M-Pro4/luc +
cells were maintained in Dulbecco modified Eagle me-
dium (GibcoBRL, Breda, The Netherlands) containing
4.5 g glucose/L supplemented with 10% FCII, 100 U/ml
penicillin, 50 μg/ml streptomycin, and 800 μg/ml ge-
neticin/G418 (Invitrogen, Breda, The Netherlands) as
described previously [28]. PCb2 [29,30] cells were derived
from PC3 cells after two passages in mice (tibiae) and
showed a higher bone metastatic capacity when com-
pared to parental cells or PC3-M cell derivatives [31,32].
The mouse monocytic cell line RAW 264.7 [33] was
kindly provided from Prof E. Tolosano, University of To-
rino, Torino, Italy. RAW264.7 cells were cultured in
DMEM (Dulbecco’s modified Eagle’s medium) containing
4.5 g/l glucose and supplemented with 10% (v/v) heat
inactivated FBS, 0.5 units/ml penicillin and 50 μg/ml
streptomycin.
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Regular cell culture dishes were coated with a film of
poly-HEMA following the protocol as previously repor-
ted [34]. Briefly, a solution of 120 mg/ml of polyHEMA
in 95% ethanol was mixed overnight, centrifuged at
800 g to remove undissolved particles and diluted 1:10
in 95% ethanol. The resulting solution was then placed
in the culture dishes. The dishes were left to dry at room
temperature overnight. Before use, the coated dishes
were washed twice with phosphate buffered saline (PBS).
Near-confluent PC3, PC2b and DU145 cells on regular
plastic tissue culture dishes were trypsinized to produce
a single cell suspension. Cells were suspended in growth
medium in the presence of 0.5% methylcellulose (to avoid
potential survival effects caused by cell clumping) in sus-
pension at a density of 500,000 cells/ml. Approximately
2.5 × 105 cells were placed in each well of a six well dish
pre-coated with poly-HEMA to prevent cell attachment.
Cell suspension was then removed from the plate, and
wells were washed with 1× PBS to collect any residual
cells. Cells pellets were obtained through centrifugation
then washed twice with 1× PBS and processed for specific
assays. At the indicated times, cells were collected, washed
with PBS and resuspended by trypsinization. Viable cells
were counted using the NucleoCounterTM NC-100
(automated cell counter systems, Chemotec, Cydevang,
DK). Apoptosis was evaluated by using Tali® Apoptosis
Kit - Annexin V Alexa Fluor® 488 & Propidium Iodide-
based, (Life Technologies Italia, Monza, Italy). Stained cells
were then measured on a Tali® Image-Based Cytometer.
Apoptosis was further confirmed by cytofluorimetric
analysis following the instructions of producer.
Migration and invasion assay
Cell migration and invasion assays were performed after
appropriate treatments using Boyden chambers con-
taining PVPF 8 μm polycarbonate filters (Nucleopore,
Concorezzo, Milan, Italy) coated on one side with 10 μg/ml
type I collagen or 25 μg/ml of matrigel (Becton Dickinson
Italia, Milan, Italy), respectively. Tests have been performed
as previously described [33].
Protease expression
The expression and activation of gelatinase A (pro-
MMP-2) and gelatinase B (pro-MMP-9) were analyzed
by zymography performed using SDS-polyacrylamide gel
copolymerized with 0.1 mg/ml gelatin [35,36]. For
plasminogen activator analysis, gels were performed
copolymerizing SDS-polyacrylamide with 0.1 mg/ml of
lactose-free casein and 15 mg/ml of human plasminogen
B as previously described [34]. Conditioned media from
PCa cells treated or not with KPT330 (7 mM) were ob-
tained from cultures grown onto 24-well plates. Following
incubation, culture supernatants were collected, centrifugedat top speed in a Eppendorf Microcentrifuge (Hamburg,
Germany) for 5 min to remove cell debris and stored
at −80°C until assayed. Corresponding monolayers were
trypsinized and the cells counted in a Neubauer chamber
(Hausser, Blu Bell, PA, USA) to normalized the gelatinase
activity of the conditioned media.
Primary cultures of mouse calvarial osteoblasts
Osteoblast cultures were derived from calvaria of 6- to
9-day-old CD1 mice. The bone samples were sequen-
tially digested with 1 mg/ml Clostridium histiolyticum
type IV collagenase (Sigma) and 0.025% trypsin in Hank’s
buffered solution. Cells from second and third digestions
were grown in DMEM with antibiotics and 10% FBS. At
confluence, cells were trypsinized, counted and plated
in appropriate vessels for experiments. The osteoblast
phenotype was evaluated by cytochemical analyses of
ALP activity using reagents and protocols from the
Sigma-Aldrich kit 104-LS. Total numbers of cells and
numbers of ALP-positive cells will be mean counts of
three microscopic fields from at least three cultures of
(magnification 20×). Moreover densitometry of the wells
was performed. Conditioned media were harvested from
sub-confluent cultures treated with serum free fresh
medium for 24 hr.
Osteoclastogenesis assay
RAW264.7 cells were incubated with PC3 and PCb2
conditioned medium collected from untreated or treated
with KPT-330 (7 μM) cells in the presence or not of
50 ng/ml RANKL. Media was replaced every 48 h and
after 5 d, cells were stained for tartrate resistant acid
phosphatase (TRAP) using Sigma TRAP staining kit
(Sigma Diagnosis, St. Louis, MO). The number of TRAP
positive cells (a measure of osteoclast activity) was deter-
mined using a light microscope. Cells were processed
further as per the protocol and differentiated osteoclasts
(with four or more nuclei) were counted. RAW264.7
cells supplemented with 5 ng/ml of RANKL only served
as negative control. In order to verify whether KPT
compounds possessed direct effects on RAW264.7 cell
differentiation, we supplemented KPT-330 to RAW264.7
cells treated with RANKL (50 ng/ml) and analyzed for
osteoclast activity and differentiation.
In vitro cytokine analyses
DU145 and PC3 cells were seeded onto 24-well plates at
a cell count of 2 × 104 cells/well in a regular culture
medium and incubated at 37°C for 48 h in the absence
and the presence of KPT-330 and KPT- 251 at con-
centrations as indicated. The conditioned medium was
collected and assayed with a sandwich ELISA for TGF-
β1 (RayBiotech, Inc., Norcross GA), IL-8 (Biorbyt ltd,
Cambridge, UK), IL6 (Biorbyt ltd), VEGF (Biorbyt ltd)
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Vinci-Biochem Florence) according to the manufactu-
rer’s protocol.
Western blot
Cytoplasmic and nuclear protein extracts were obtained
by using the Nuclear/Cytosol Fractionation Kit, Catalog
#K266-25, from Biovision Inc. (Milpitas, CA, USA). Cell
extracts and Conditioned media from treated and un-
treated cells were electrophoresed under reducing condi-
tions and transferred to nitrocellulose filter (Schleicher
and Schuell GmbH, Dassel, Germany). Non specific bin-
ding sites were blocked for 1 h in 5% non-fat dried milk
in a Tris buffer containg 20 mM tris and 137 mM NaCl
(pH 7.6). Blots were incubated with 1 μg/ml of primary
antibody diluited in blocking solution for 1 h at room
temperature, washed and then incubated for 1 h in sec-
ondary antibody diluted 1:3000 in blocking solution.
Following a further wash, reactive bands were visualized
by a chemiluminescent detection kit (Supersignal, Perbio
Science, Tattenhall, UK) b y using Bio-Rad gel Doc™
(Bio-Rad Laboratories S.r.l., Miulan, Italy).
In vivo treatments
Orthotopic model
Eight week old male SCID mice (Charles River, Calco,
Como) were used. Experimental protocols were approved
by the Ethics Committee for Animal Experimentation of
the Fondazione IRCCS Istituto Nazionale dei Tumori
(Milan, Italy). Mice were housed in a pathogen-free facility
with food and water available ad libitum. Animal were
anesthetized using a solution of Ketamine (100 mg/kg)
and Xylazine (20 mg/kg), delivered i.p. in a volume of
10 ml/kg of body weight. All surgical procedures were car-
ried out in sterile condition under a 10 × microscope
(SMZ800 Nikon). Briefly, abdominal wall muscles were in-
cised, and the bladder and seminal vesicles were delivered
through the incision to expose the prostate. One million
DU-145 cells in 50 μl of RPMI were injected in the right
posterior prostatic lobe using a 1 ml syringe with a 27
Gauge needle [32,37] The incision was closed with Poly-
glactine 910 (Vicryl 5–0) and surgical staples. Experiments
were started when tumors were palpable. A tumor was
defined as “palpable” when it is detected by palpation and
confirmed upon histological analysis (performed in a
couple of mice that were sacrificed to this purpose). At
35 days after cells injection, when intraprostatic tumors
were palpable, mice were randomized into experimental
groups (8–9 mice/group) to receive either vehicle or
KPT-330. At this time, tumor weight was about 100 mg.
Such a tumor weigh is a common starting point for drug
activity evaluation in human tumor xenografts subcutane-
ously or orthotopically implanted. The drug was dissolved
according to Karyopharm’s instructions and delivered byoral gavage 2 times a week for 7 times at a dose of
10 mg/kg or every day for 5 days at dose of 4 mg/kg.
All mice were monitored biweekly for tumor onset. At the
end of the experiment (65 days after cell injection), all the
mice were anesthetized and sacrificed for the evaluation
of drug efficacy. At necroscopy, intra-prostate tumors
were collected and weighted. Peritoneal surface and
diaphragm were inspected macroscopically for the pres-
ence of metastatic nodes and tumor specimens were
fixed in 10% buffered formalin for subsequent histo-
logical analysis.
Intracardiac tumor model
Heart injection of PCb2 cells was performed as previ-
ously described [29,30]. Briefly, a 27 gauge needle on a
tuberculin syringe containing 1 × 105 tumor cells in
0.1 ml of PBS was inserted in the second left inter-
costal space of male CD1 nu/nu mice. Two days after
treatments with XPO1 inhibitors, Selinexor [10 mg/Kg
(q 2d × 3 weeks) or KPT-251 [100 mg/Kg (q 2d × 3 weeks)
p.o.] were started (Figure 1A). We used alendronate
(0.05 mg/kg s.c.) as internal positive control since in our
previous experience demonstrated to be able to reduce
osteolysis [38]. All treatments were started two days
after cell injection in order to study how XPO1 inhib-
itors affect the growth of a limited number of tumor
cells within bone marrow. This experimental model
mimics the clinical condition of patients without clin-
ical evidence of bone lesions but at high risk of bone
metastasis development (e.g., with castration resistant
PCa). The development of metastases was monitored
by radiography using a Faxitron cabinet x-ray system
(Faxitron x-ray corp., Wheeling, IL, USA ). Radiogra-
phic analyses were performed at days 28, 35, 42 and
50 after cell injection. No Faxitron analysis was per-
formed after the 50th day since after this time the
estimated risk of anesthesia-related mortality of mice
was significantly increased. However, in order to de-
termine both cumulative incidence of bone metastases
and disease free survival (DSF), X-rays were also re-
peated at the death of each animal or in the survived
animal at the end of follow-up, that we have defined
to be 170 days, when animals were sacrificed. We previ-
ously demonstrated [29] that intra-ventricular injection
indicate a low probability of developing forelimb tumors
and high probability of developing hind limb tumors. For
this reason we have focused on analyzing the metastases
in the hind femurs and tibias. Burden of osteolytic lesions
was evaluated by digital examination of radiography
(ImageJ, a public domain software by Wayne Rasband,
NIH, USA). Animals were sacrificed by carbon dioxide
inhalation 170 days after heart injections, or earlier if there
were early signs of serious distress. All animals were
subjected to an accurate post mortem examination
Figure 1 Pharmacological treatment with XPO1 inhibitors reduces incidence and increases survival in a model of prostate cancer
derived bone metastasis. (A) In vivo schematic representation of the treatments in bone metastatic PCb2 model. (B) Representative X-ray
pictures of untreated (vehicle), alendronate or selinexor ( KPT-330) and KPT-251 treated mice collected at 50th day after intracardiac cell injection
and showing strong osteolysis in untreated animals, moderate osteolysis in alendronate and KPT-251 treated animals and no lesions in selinexor
treated animals. (C) table summarizing incidence and osteolysis (Lytic units) as measure of tumor burden at 35, 42 and 50 days after tumor inoculation
and treatments. (D) serum CTX-I and (E) mTRAP levels measured in control animals and upon treatments. Both panels show the levels of CTX-I and
TRAP measured before the death of the animals or in survived animal at the end of follow-up (170 days) (F) Visceral metastases incidence upon
treatments in intact nude mice intracardiacally injected with PCb2cells. *P at least <0.05.
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histological analyses.
Intratibial tumor model
Intratibial tumor injection was performed as previ-
ously described [31,32,39]. Briefly, luciferase transfected
PC3Luc cells were injected at 2 × 105 cells/10 μl of serum-
free medium into the proximal tibiae of 4-week old male
CD1 nu/nu mice. The development of metastases wasmonitored by using a Faxitron cabinet x-ray system and
tumor burden evaluated by bioluminescence analyses
(see below).
Treatments of bone metastases models
Before drug administration, animals were divided into
four groups (n = 10) and treated by oral gavage: Group 1
receiving vehicle control (Pluronic F-68/PVP-K29/32),
Group 2 receiving KPT-251 [100 mg/Kg (q 2d × 3 weeks)
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3 weeks) p.o.]: group 4: mice (10 animals) receiving alen-
dronate (0.05 mg/kg s.c.).
Assessment of treatment response in bone metastatic models
Tumor and bone treatment response was determined
using X-rays as well as histomorphometric analyses of
H&E stained sections. Skeletal lesions were calculated as
described by Yang et al. [40], where 0 = no X-ray detectable
lesions, 1 =minor lesions, 2 = small lesions, 3 = significant
lesions with minor break of margins, or 4 = significant
lesions with major break of margins.
Bioluminescence analyses
For luminescence imaging, mice received 150 mg firefly
luciferase (Synchem Ug and Co.KG, Felsberg-Altenburg,
Germany) per kg body weight given intraperitoneally.
Following anesthesia with ketamine/xylazine mixture
mice were placed into a Hamamatsu imaging station
(Hamamatsu photonics, Italian distributor, Rome Italy).
Bioluminescence generated by the luciferin/luciferase
reaction was used for quantification using a dedicated
Living Image software on a red (high intensity/cell number)
to blue (low intensity/cell number) visual scale. A digital
grayscale animal image was acquired followed by acquisi-
tion and overlay of a pseudo-color image representing the
spatial distribution of detected photon counts emerging
from active luciferase within the animal. Signal intensity
was quantified as the sum of all detected photons within
the region of interest during a 1-minute luminescent inte-
gration time. Tumor incidence was scored on a dichotom-
ous scale as being either positive or negative if animals
had at least one lesion detected in either the humeri or
tibia/femur region.
Manipulation of bone metastatic tissues
For histologic examination, tibiae and femurs were dis-
sected, cleaned from soft tissues, and fixed in 4% formal-
dehyde in 0.1 mol/L phosphate buffer (pH 7.2). Samples
were then decalcified in EDTA and embedded in paraffin.
Sections were cut and stained with H&E to evaluate the
displacement of bone marrow by tumor cells as well as
the tumor diameter.
Tartrate-resistant acid phosphatase staining
For the detection of osteoclasts, TRAP staining was done
using Sigma Diagnosis Acid Phosphatase Kit. The number
of TRAP-positive osteoclasts at the tumor-bone interface
was counted under a microscope within 5 individual mi-
croscopic 200× fields.
Serum levels of CTX-I and TRAP-5b
Blood samples were collected from the tail of animals at
defined times. For the intraventricular model we collectedblood samples every two weeks or when the general
conditions of the animals were indicative of impend-
ing death. For the intra-tibial model blood samples
were collected at 10, 15, 28 and 35 days. Measurement of
serum Mouse cross linked C-telopeptide of type I collagen
(CTX-I, USCN Life Science Inc., Houston, TX) and mouse
TRAP-5b (mTRAP, MyBioSource, Inc., San Diego, CA)
were performed according to the manufacturer’s protocol.
Blood without anticoagulant agents was collected, allowed
to clot and then centrifuged at 2,000 × g for 10 min to ob-
tain serum, which was stored at −20°C until further assay.
Statistical analysis
Continuous variables were summarized as mean and S.D.
or 95% CI for the mean. Statistical comparisons between
controls and treated groups were established by carrying
out the ANOVA test or by Student’s t test for unpaired
data (for two comparisons). Dichotomous variables were
summarized by absolute and/or relative frequencies. For
dichotomous variables, statistical comparisons between
control and treated groups were established by carrying
out the exact Fisher’s test. For multiple comparisons, the
level of significance was corrected by multiplying the P
value by the number of comparisons performed (n) accor-
ding to Bonferroni correction. Overall and Disease-Free
survival were analyzed by Kaplan–Meier curves and
Gehan's generalized Wilcoxon test. When more than two
survival curves were compared, the Logrank test for trend
was used. This tests the probability that there is a trend in
survival scores across the groups. All tests were two-sided
and were determined by Monte Carlo significance. P
values <0.05 were considered statistically significant. SPSS
(statistical analysis software package, IBM Corp., Armonk,
NY, USA) version 10.0 and StatDirect (version. 2.3.3.,
StatDirect Ltd, Altrincham, Manchester, UK) were used
for statistical analysis and graphic presentation.
Results
Selinexor (KPT-330) and KPT-251 reduce incidence of
bone metastasis and increases survival of mice with bone
metastases after intraventricular injection of tumor cells
PC2b cells, an aggressive variant of PC3 cells, were in-
jected in CD1 nu/nu male mice treated accordingly to
the schema in Figure 1A. Forelimb osteolytic bone
lesions (Figure 1B) appeared in control mice at day 35
post-inoculation in 3 out of 10 (30%) mice and progres-
sively increased to 80% (8/10) at the 50th day (Figure 1C).
In contrast, no osteolytic lesions were detected until day
50 in KPT-251 treated animals (2/10, Figure 1C) although
the overall incidence at the end of experiment (day 170)
was 50% (5/10). Interestingly, 0/10 animals showed bone
metastases after Selinexor treatment in any X-ray analysis
(P < 0.0001 vs vehicle-treated animals) and no animals had
bone lesions at the end of experiment (day 170), whereas
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(P < 0.05 vs vehicle-treated animals). Bone lysis measured
as lytic units was significantly higher in CTRL with
respect to KPT-251 (p < 0.05) (Figure 1C) whereas no
osteolysis was observed after Selinexor treatment. In
agreement with previous data literature, alendronate treat-
ment did not alter the incidence of bone lesions, but
tumor-induced osteolysis was reduced [41-43]. Serum
levels of CTX-I (Figure 1D) and mTRAP5b (Figure 1E),
two specific markers of bone reabsorption, were sig-
nificantly lower in the KPT-251 in treated animals with
respect to CTRL (p < 0.005) and this paralleled with the
reduced bone lysis found in these animals. In Selinexor
treated animals, the levels of these markers were similar
to those observed in animals which underwent empty
injections without tumor cells and significantly lower than
levels in CTRL and KPT-251 treated groups (p < 0.001).
Not statistical significance were observed between alen-
dronate and CTRL groups, whereas both KPT251 and
KPT-330 treated animals showed significantly lower levels
of CTX and mTRAP to those measured in alendronate-
treated animals (p < 0.005). Post-mortem necroscopy doc-
umented lower incidence of lymph node, lung and liver
metastases upon KPT 251- and Selinexor- treatments
(Figure 1F). However, the one animal that died in the
KPT-330 treated group had a large lung metastasis and in-
volvement of loco-regional lymph nodes.
The Kaplan-Meier curves showed that KPT-251 and
Selinexor both improved DFS (Figure 2A-B) and OS
(Figure 3A-B) of mice with bone lesions obtained by
intracardiac injection compared with CTRL and mice
treated with alendronate. However. no statistically sig-
nificant difference was found between KPT-251and
KPT-330 treated animals in terms of DFS and OS.
Anti-metastatic effects is affected by number of tumor
cells within bone marrow
In order to discern if the number of tumor cells within
bone marrow (i.e., the intraosseous tumor burden) was a
variable related to the effectiveness of KPT-251 and
Selinexor in terms of reduced incidence of bone me-
tastases, Luciferase-transfected PC3 cells were directly
injected into tibia of nude mice. This model allowed
us to inject a substantially higher number of tumor
cells within bone marrow in comparison with the intracar-
diac tumor model. Consistent with our previous data
[29,30], 3 to 5 days after intra-tibial tumor cell injection,
bioluminescence imaging revealed a significant intraoss-
eous presence of PC3-Luc cells in all injected mice. BLI
analyses were confirmed to be osteolytic lesions whose
intensity was correlated with the size of bone metastasis
(Figure 4A). Tumor cells grow in the bone marrow in
close proximity with the trabeculae of the proximal
epiphysis and very few cytokeratin positive cells are foundin the bone marrow of selinexor treated mice (Figure 4B).
All CTRLs were shown to have radiologically evident
lesions and tumor cell component was prevalent in CTRL
animals in comparison with Selinexor treated animals.
Selinexor reduced the growth of tumor cells in the
bone marrow as indicated to the changes in luciferase
signal (Figure 4C). Also KPT-251 treatment reduced
tumor growth (lower BLI intensities, Figure 4C) and
lower incidence of radiographic lesions with high scores
(Figure 4D,E) in comparison with CTRL. Osteolysis was
also reduced as indicated by reduction in X-ray scores
(Figure 4D,E) and osteoclast number (Figure 4F). Osteo-
clasts number was calculated by the direct count of purple
staining TRAP positive cells (osteoclasts) at the interface
tumor/bone. We considered for this analyses tibiae having
a score higher of 1 since was difficult to found a sufficient
area in which tumor cells were in contact to bone trabe-
culae. Therefore we analyzed three different sections of
10/10 tibiae of control mice, 7/10 tibiae of mice treated
with KPT251 and 5/10 tibiae of mice treated with seli-
nexor. We found that osteoclast number was, however,
proportional to extension of lytic lesions and very similar
in animals having similar lesions also if different treat-
ments were administered. Nevertheless, osteoclast num-
ber was higher in control animals (11.2 +/− 5.4 cells/filed)
when compared to selinexor (5.3 +/− 3.6) or KPT251
(8.4 +/− 2.6) treated animals also if statistical significance
was observed only in selinexor treated mice (p = 0.033).
Reductions in the serum levels of CTX-I and TRAP5b in
treated versus CTRL animals (Figure 4G,H) confirmed
once again the ability of Selinexor and KPT-251 in redu-
cing osteoclast activity.
Selinexor reduces tumor spread of PCa cells
orthotopically injected into prostate gland
To further confirm that XPO1 inhibition may represent
a therapeutic strategy in PCa, we used this orthotopic
model to determine if SINE compounds could control
local disease. In particular, we used the DU145 cells line
which have not elevated capacity to metastasize, also if
causes wide visceral diffusion when injected into prostate
gland [44]. Since our experimental evidence in bone
metastatic models suggest that Selinexor possesses higher
antitumor and anti-bone metastatic activity when com-
pared with KPT-251, Selinexor was used for the prostatic
orthotopic experiments. SINE treatment was started when
prostate (tumors) were palpable.
At day 65 (i.e., 26 days after the last treatment with
Selinexor 4 mg/kg, and 7 days after last treatment with
Selinexor 10 mg/kg), mice were sacrificed for evaluation
of antitumor activity. Selinexor induced statistically signi-
ficant tumor weight inhibition compared to CTRL mice
(41%, p < 0.01, for 4 mg/kg, and 61%, p < 0.01 for 10 mg/k,
respectively, compared with CTRL). In addition, while a
Comparison of DFS curves (Logrank test)
Endpoint observed n. 10.0 8.0 0.0




Comparison of DFS curves (Logrank test) for trend
Chi-square (trend) 22.2207
DF 1
Signiﬁcance  level P<0.0001
Comparison of median DFS (0ne-way Anova on Log transformed data)
Source of variaon Sum of squares DF Mean squares
Between groups (inﬂuence factor) 1.9241 3 0.5414




Post-hoc Student-Newman-Kreutz test for all pairwise comparisons
treatments n. Geom. Mean Diﬀerent (P<0.05) among treatments
CTRL 10 50.7551 (KPT251; KPT330)
Alendronate 10 56.2306 (KPT251; KPT330)
KPT251 10 117.5360 (CTRL; Alendronate)
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Figure 2 Intraventricular cell injection. (A) Analysis of Disease Free Survival by Kaplan-Meier curves and logrank test upon KPT-251, KPT-330
and alendronate treatments. (B) Median Disease Free Survival, one-way Anova on log-transformed data and post-hoc Student-Newman-Keults test
for all pair wise comparisons.
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face and diaphragm was recorded in 8 out of 9 control
mice, the presence of metastatic nodes was appreciable in
only 4 out of 7 mice treated with the daily schedule
(4 mg/kg × 5 consecutive days) of KPT and in no animal
treated with the biweekly schedule (10 mg/kg × 7 admin-
istrations). Toxic effects in this model were in 1 of 8
and 2 of 8 mice in the 4 mg/kg and 10 mg/kg respectively
(Figure 5).
Selinexor treatment amplifies anoikis in prostatic cancer
cells with high metastatic potential
In order mimic the effects that Selinexor may have
on cell viability of tumor cells which extravasate in
the blood and lymphatic stream, we grew PC3, PCb2
and DU145 cells in polyhema-treated dishes which
prevents cell attachment. We hypothesize that Selinexor
may accelerate this apoptotic process determining a
strong reduction of cells which can establish metastatic
lesions. The lack of anchorage-dependent cell growth isassociated to metastatic process both in the detachment
and invasive (extravasation) phase. Anoikis is a form of
programmed cell death which is induced by cells detach-
ing from the surrounding extracellular matrix (ECM).
Usually cells stay close to the tissue to which they belong
since the communication between proximal cells as well
as between cells and ECM provide essential signals for
growth or survival. When cells are detached from the
ECM, i.e. there is a loss of normal cell–matrix interac-
tions, they may undergo anoikis. To verify if KPT330 was
active inducing or amplifying anoikis, PCa cells were
treated with sub-toxic concentrations of Selinexor (20
and 50 nM) corresponding to the IC10 and IC20
values for this compound [45]. We chose the dose of
50 nM since this is the pharmacological plasma concen-
tration obtained administrating 4 mg/Kg day. In Figure 6A,
we show that the percentage of cells which died following
Selinexor treatment in presence of polyhema was 3.6 fold
higher compared to cells grown in adhesion conditions
(Figure 6B), suggesting that a portion of “extravasate cells”
Figure 3 Intraventricular cell injection. (A) Analysis of Overall Survival by Kaplan-Meier curves and logrank test upon KPT-251, selinexor (KPT-330)
and alendronate treatments. (B) Median Overall Survival, one-way Anova on log-transformed data and post-hoc Student-Newman-Keults test for all
pair wise comparisons.
Gravina et al. Journal of Hematology & Oncology 2014, 7:46 Page 9 of 17
http://www.jhoonline.org/content/7/1/46could die during treatment with Selinexor. In Figure 6C
we show the anoikis FACS profile collected from
DU145 and treated with 20 and 50 nM Selinexor.
Anoikis was associated with modulation of bcl2 fam-
ily members as indicated in Figure 6D. In particular,
Bcl2 and BclXl levels were significantly reduced in the
time by Selinexor treatment whereas BclXs and Bax levels
were increased.
Selinexor reduces migration and tumor invasion by
reducing MMP-9, MMP-2 and uPA secretion
To study the effects of Selinexor on tumor cell migration
and invasion, specific assays by using Boyden chambers
were performed. Cells were pre-treated with Selinexor and
in the inferior compartment of Boyden chamber osteo-
blast conditioned medium was used as chemotractant.
Also in this case we chose the dose of 50 nM since this is
the pharmacological plasma concentration obtained ad-
ministrating 4 mg/Kg day We demonstrated that osteo-
blast conditioned medium increased significantly cell
migration and invasion of PC3, DU145 and PCb2 cellsand Selinexor (50 nM) efficiently inhibited cell migration
and matrigel invasion (Figure 7A,B). Interestingly, re-
duced migratory and invasive properties were coupled
with down regulation of MMP-9, MMP-2 and uPA secre-
tion (Figure 7C), with reduced protease/tissue inhibitor
ratios. Immuno-cytochemical and western blot analyses
performed on cell extracts from cultured cells with or
without Selinexor (50 nM), revealed an increased and
prevalent nuclear localization of p27, survivin, CRM1,
ELAV-1, ILK and PAK-4, whereas controls showed a low
level and cytoplasmic-prevalent localization (Figure 7D).
Survivin has been implicated in cell division and apop-
tosis. Its cytoplasmic localization is essential for their
inhibitory effects on caspases activity and apoptosis. CRM1
activity and localization is modulated by Akt/mTOR path-
ways. Increased nuclear localization of CRM1 by TORC1/
TORC2 [46] or pan HDAC [47] inhibitors has been asso-
ciated to apoptotic effects of these compounds through
reduced survivin levels in the cytoplasm. Interestingly,
Selinexor also increased the nuclear expression of ILK
and PAK-4, two proteins associated with the migration
Figure 4 Intratibial injection of PC3 cells. Treatments with KPT-251 and selinexor (KPT-330) started two day after cell inoculation. (A).
Representative X-ray and bioluminescence pictures of untreated (vehicle) or KPT-251 and selinexor treated mice collected at 50th day after
intratibial cell injection. (B) Tibiae injected with PC3M-pro4 luc cells from mice of controls (CTRL) and treated with KPT330 and visualized at low
(100×) and high (400×) magnification. This panel presents in the upper side a hematoxylin/eosin staining showing a strong tumor cell
colonization and very low/absent tumor cell colonization which is detected by immune-hystochemical evaluation of cytocheratin 18 (K18). In
the CTRLs tumor cell form a compact structure with reduced bone stroma cell presence. Tumor cells colonize also the cortical bone after having
supporting osteolysis. No PC3 tumor cell colonization associated with any macroscopic variations in the bone stroma cell population was
evident after KPT330 treatments. Tr (bone trabecula), Bm (bone marrow), Tc (tumor cells). (C) graph showing the percentage of change in
luciferase signal. (D) Number of radio logically evident intratibial bone lesions having scores ≤ 2 and ≥ 3 according to Yang et al. procedure
[40]. (E) X ray scores. (F) osteoclast number evaluated in the bone metastatic lesions. Osteoclasts are visible as histochemical purple staining for
TRAcP activity as a marker of osteoclasts. Data are expressed as number of osteoclasts/mm at the tumor–bone interface. Number of osteoclasts
was proportional to the lysis score but no statistical significance was observed. NE = not evaluable. The NE cases were excluded by analyses.
(G) mTRAP and (H) CTX-I levels in controls and upon 35 days of KPT-330 and KPT-251 treatments in intratibial injected mice with PC3 cells.
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levels of total ILK (Figure 7D). We analyzed p27 and ILK
expression in cytoplasm and nucleus extracts by using aprotein loading control β-actin and lamin B, respectively.
The same loading controls were used to verify the purity
of cytoplasm and nucleus extracts.
Figure 5 Orthotopically implanted DU-145 human prostate carcinoma cells. At day 65 (i.e., 26 days after the last treatment with selinexor
(KPT-330) at the dose of 4 mg/kg, and 7 days after last treatment with selinexor at the dose of 10 mg/kg) mice were sacrificed for evaluating
antitumor activity of the drug. (A) table summarized the pharmacological effects of selinexor including Toxicity, Body weight Loss (BWL), tumor
mass weight, tumor mass reduction and macroscopic dissemination in the peritoneal surface and diaphragm. (B) single tumor mass weight in
different treatment groups. (C) percentage of mice with macroscopically evident dissemination.
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differentiation and activity in RAW264.7
To examine the effect of Selinexor on tumor angio-
genesis, the expression levels of angiogenetic cytokines
(IL-8 and VEGF) were measured in conditioned medium
(CM) collected from PC3 and DU145 cultured with
SDF-1α cells and treated with Selinexor. Significantly
higher levels of IL-8 and VEGF were found in controls
compared with Selinexor treated cells (Figure 7E,F). PCa
cell-induced osteoclastogenesis was analyzed on monocyte-
like RAW264.7 cells by using conditioned medium (CM)
collected from PC3 cells untreated or treated with CTRL or
with Selinexor. RANKL, at the concentration of 5 ng/ml,
was used to boost the osteoclastogenesis and 5 days later,
the levels of mouse tartrate-resistant acid phosphatase
(mTRAP), a marker of osteoclast differentiation, was mea-
sured in RAW264. 7 cells by enzymatic assay performed
in total extracts. High levels of mTRAP were found in cul-
tures treated with CM from untreated PC3 cells while
lower levels were found in RAW264.7 cells treated with
CM from Selinexor treated PC3 cells (Figure 8A-C). Neg-
ligible, if any, differentiated osteoclasts were observed in
RAW264.7 cells treated with 5 ng/ml RANKL alone.
Selinexor showed antiproliferative effects on RAW264.7
(data not shown) In the context of bone metastasis,
however, tumor cells could induce the expression ofosteoclastogenic factors [42,48,49]. Therefore, we tested
whether selinexor could modulate the ability of PC3 to se-
crete osteotropic cytokines such as IL-6, IL-8, TGF-β1 and
RANKL. We showed that PC3 cells treated with Selinexor,
at a low concentrations (IC20), produced significantly
lower IL6 (Figure 8D) with reduced effects on the expres-
sion of other pro-osteoclastogenic cytokines, including
RANKL [46], IL-8 [47], TGF-β1 [48] (Figure 8E-G).
Discussion
PCa cells are highly dependent upon the microenviron-
ment where cytokines and contact with stromal cells pro-
mote cell activation and proliferation as well as resistance
to spontaneous and drug-mediated apoptosis. Like many
oncogenic and growth related pathways, many of these
microenvironment-activated pathways intersect with TSPs
which are exported from the nucleus by XPO1, leading to
their functional inactivation [7,11-16]. XPO1 inhibition
leads to CRM1 nuclear localization with forced accumula-
tion of TSPs in the nucleus determining reduced onco-
genic functions. Thus, the concept of inhibiting XPO1 has
been explored as a potential therapeutic intervention
using clinically relevant orally bioavailable SINE com-
pounds. We have previously demonstrated that the inhib-
ition of XPO1 with SINE reduced the cell and tumor
growth in PCa preclinical models inducing G2/M cell
Figure 6 In vitro experiments: Selinexor (KPT-330) amplified anoikis in prostatic cancer cells with high metastatic potential. (A) this
panel shows the cell death percentage in PC3, PCb2 and DU145 cells treated or not with 20 or 50 nM KPT-330, corresponding to IC10 and IC20
values for this compound [18], and grown in non adhesion conditions (anoikis). (B) This panel shows the cell death percentage obtained in the
same cells treated or not with KPT and grown in adhesion conditions (apoptosis). (C) This panel show the FACS analyses evaluated in DU145
treated with 20 and 50 nM KPT-330 grown in non adhesion conditions (anoikis). (D) Selinexor reduces migration and tumor invasion by reducing
MMP-9, MMP-2 and uPA secretion.
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used: (i) DU145 cell line, injected orthotopically in pros-
tate gland of SCID mice, to study the anti-metastatic
effects of KPT330 and KPT251; (ii) PCb2 cell lines,
derived from PC3 cells after serial intra-bone growth in
mice, intra-ventricularly injected in male nude mice to
mimic an aggressive prostate cancer with no evident bone
metastasis and (iii) luciferase transfected PC3 cells for the
intratibial injection to study the intra-bone tumor growth.
The choice to use two different PC3 derivatives arose by
the experimental convenience to obtain the higher inci-
dence rate of bone lesions with PCb2 cells, as widely
demonstrated by our research group [29,30] when the in-
tracardiac model was used and by the fact that luciferase
transfected PC3-M-pro4 cells were widely characterized
[28] and kindly provided from G van der Pluijg. The use
of luciferase transfected cells serve to identify little not
radiologically evident bone lesions also if bioluminescence
analysis has the main disadvantage to have a low spatial
resolution whereas bioluminescence intensity is propor-
tional to cells present in a tumor. Therefore biolumines-
cence allows to have a good quantitation of tumor burden
when PC3 cell growth destroys the bone and extents
outside of it. X-ray is a well-established and referencedmodality to longitudinal monitor bone lesions in small
animals with a good spatial resolution. Intracardiac ex-
periments showed very few fractures and extra-bone le-
sion before animals died whereas intratibial experiments
showed larger bone lesions with fractures and extra-bone
growth. For this reason the non- use of PC3-luc cells in
the intra-ventricular injection has allowed us to have an
easy and direct comparability with those obtained in
humans. Inter- and intra-observer variability have been
partially mitigated by the use of Image-J, a software
widely used in the objective quantification of bone lesion
extension.
To our knowledge, this manuscript is the first report
showing that SINE XPO1-antagonists show anti-metastatic
properties. Our data suggest that SINE compounds, and
Selinexor in particular, could achieve these effects through
several mechanisms: (i) inhibiting the survival and inducing
apoptosis of circulating metastasizing cells; (ii) reducing
the migration and the invasion of metastasizing cells; (iii)
reducing bone colonization by metastatic cells; (iv) redu-
cing the tumor burden both in the primary and in bone
sites; (v) reducing the survival and probably differentiation
of osteoclast progenitors. The first two statements born
from data shown in Figures 6 and 7 in which we observed
Figure 7 Selinexor (KPT-330) reduces migration and invasion of DU145, PCb2 and PC3 tumor cells. (A) migration test with treatment with
50 nM KPT-330 by using Boyden chambers and osteoblast conditioned medium as chemotractant. (B) invasion test in the same experimental
conditions. (C) Deregulation of MMP-9, MMP-2 and uPA secretion after selinexor treatment. (D) time-dependent variation in the levels nuclear and
cytoplasm levels of P27 and ILK after treatment with selinexor. Each Western Blot lane was loaded with 40 μg of proteins and normalized vs b-actin
(cytoplasm levels) and lamin B (nuclear levels). (E) VEGF measured by ELISA and performed on conditioned media from cells treated or not with 20 or
50 nM selinexor. (F) Il-8 measured by ELISA and performed on conditioned media from cells treated or not with 20 or 50 nM selinexor.
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available XPO1 inhibitor, was able to increase apoptosis
(anoikis) when PC-b2 and DU145 tumor cells were seeded
in tissue culture dishes coated with poly HEMA and thus
forced to grow in suspension. Under these conditions,
indeed, both the number and the size of cell spheroids
were significantly reduced and apoptosis was significantly
greater after Selinexor treatment when compared with
controls. Selinexor was also able to inhibit PC3, PCb2
and DU145 cell migration, and this correlated with
p27 and ILK nuclear accumulation in agreement with data
reported by Wang [50] and Nakrieko [51], respectivelydemonstrating that the cell cycle inhibitor p21-Cip and
p27-Kip proteins play unique roles outside of the nucleus
regulating actin dynamics and cell migration. In addition
we observed also a significant decrease of cytoplasmic
PAK4, a well known kinase involved in β-catenin mediated
Epithelial Mesenchymal Transition (EMT), after selinexor
treatment [52]. These results are strongly suggestive for a
reduced invasive capacity of selinexor treated cells. More-
over, selinexor treatment induced segregation of CRM1
and ELAV1/HuR in the nucleus. Being ELAV1/Hur a
member of RNA-binding proteins that selectively bind
AU-rich elements, AREs, found in the 3′ untranslated
Figure 8 Selinexor (KPT-330) inhibits PCa cells-Induced osteoclast differentiation in the RAW264.7 cell model. (A) cytochemical
evaluation of mouse TRAP in RAW264.7 cells treated with PC3 conditioned medium when these cells were cultured in the presence or not of
0.7 μM selinexor. This concentration was the IC20 value for RAW264.7 cell and was easily reached in vivo when 10 mg/Kg (q 2d × 3 weeks)
KPT-330 was administered in the mice. Osteoclasts are large polinucleated TRAP + cells. (B) TRAP + polinucleated cells were counted and plotted
in a graph considering a total count of 500 cells. (C) cells were collected and lysed to evaluate the enzymatic mTRAP activity. (D) IL-6, TGFb1 (E) and
(F) RANL levels measured in osteotropic PC3 and PCb2 cells treated with 20 and 50 nM selinexor.
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could destabilize ARE-containing mRNAs [53] and re-
duced protein synthesis including angiogenetic cytokines,
VEGF-a and IL8, and proteases involved in the degrad-
ation of extracellular matrix proteins such as MMP-9,
MMP-2 and uPA. Effectively, also in PCa cells we demon-
strated that selinexor inhibited VEGF-a and IL-8 secretion
as well as the expression and activity of MMP-9, MMP-2
and uPA as has been demonstrated for the natural product
XPO1 inhibitor leptomycin B [54,55]. However, the cur-
rent report is the sole evidence that clinically relevant,
small molecule SINE compounds reduce MMP-9 and
angiogenesis in PCa. ELAV1 has been, indeed, indicated as
a potentially useful target for cancer diagnosis, prognosis,
and therapy of tumors [56].In vivo experiments demonstrated that Selinexor and
KPT-251 reduced also tumor growth and visceral metas-
tases when DU145 cells were injected in the prostate
gland (orthotopic model) of mice. The reduced incidence
of visceral metastases was also associated to reduced
angiogenesis evaluated as vessel count performed in pros-
tate glands and seminal vesicles containing DU145 tumors
and this was in agreement with our in vitro results. This
anti-angiogenic effect provides a further obstacle to ex-
travasation/intravasation of metastatic tumor cells. We
demonstrate also that visceral metastases and osteolytic
lesions were also reduced after treatment with selinexor
or KPT251 when the intra-ventricular model were used.
Selinexor resulted to be more potent of KPT251. This de-
termined a significant increase in the disease-free survival
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and KPT251 affected intra-osseous tumor growth when
PC3 cells were inoculated directly in the tibia where these
agents impaired also osteoclastogenesis. In this model,
areas of osteolytic lesions and tumor growth were signifi-
cantly reduced by CRM1 inhibitors: also in this case
KPT330 resulted to be more potent respect to KPT251.
The degree of bone resorption in bone metastases in-
fluences the course of disease and serum markers of
N-telopeptide type I collagen (CTX) has been shown
to be predictive of SREs, bone disease progression, and
death [57]. Therefore we analyzed CTX-I and mTRAP, a
marker of osteoclasts, to have a further indication of
reduction of tumor-derived bone osteolysis. We found
that Selinexor and KPT-251 significantly reduced the
levels of CTX-I in PCa bearing mice. In addition, also
mTRAP levels were significantly reduced by XPO1 inhib-
ition. These data are in agreement with Tai and coworkers
[58] demonstrating that XPO1 inhibition induced tumor
cell cytotoxicity and impaired osteoclastogenesis in mul-
tiple myeloma. These authors found that XPO1 SINEs
directly impaired osteoclastogenesis and bone resorption
with minimal impact on osteoblasts and bone marrow
stromal cells. Extending the data reported by Tai and
coworkers, we observed that XPO1 inhibition can me-
diate a reduction in osteolysis directly through effects
on bone cells. We observed that count of TRAP posi-
tive cells (osteoclasts) in the bone metastases were
significantly reduced after treatments as reduced was
the growth of osteoclast precursors, modeled by using
monocyte-macrophage RAW 264.7 cells. RANKL induced
TRAP activity and the formation of multinucleated
cells (osteoclasts) in RAW 264.7 cell population and
this phenomenon was significantly reduced by Selinexor
administration suggesting that osteclasts was not pro-
duced. We observed also that Selinexor induced cytotoxic
effects on RAW264.7 cells that were lower, in terms of
inhibition percentage, to those observed for osteoclast
formation suggesting that selinexor could affect also
osteoclast diffentiation in agreement with Tai and co-
workers [58]. Furthermore, we observed that selinexor
reduced also RANKL secretion by tumor cells in agree-
ment with the report by Tai and coworkers in myeloma
[58]. However, this suggestions are not conclusive to state
that selinexor shows main effects on osteoclasts to deter-
mine reduction of osteolysis. Progression of the estab-
lished skeletal PCa tumors is, indeed, supported by the
mutual interplay between locally increased osteoclastic
[11,16] and osteoblastic [36,59] activity and tumor cell
proliferation (the “vicious cycle;”), which may also facili-
tate earlier steps in skeletal tumor establishment and de-
velopment. Therefore, SINE induced reduction in tumor
progression observed following RANKL inhibition is likely
the consequence of interrupting the “vicious cycle,” whichleads to a reduction in local concentrations of bone-
derived factors as a result of lower osteoclastic bone
resorption. As osteoclast-mediated bone destruction has
been reduced by SINE treatment, the reactive osteoblastic
activity is also reduced. That report in myeloma is the sole
report, in addition to ours, demonstrating that SINEs im-
pair bone remodeling after primary cancer (myeloma) and
bone metastasis (prostate cancer). Taken together, these
effects translate in the reduced incidence of metastases
and SREs and increased overall survival of SINE-treated
animals.
Conclusions
Our data show that selective blockade of XPO1-dependent
nuclear export with small molecule, drug-like SINEs repre-
sents a completely novel approach for the treatment of
subjects with primary tumors at high risk of visceral and
bone metastatic spread. The SINE compounds actively pre-
vent visceral and bone metastasis of PCa cells, and impair
PCa induced osteoclastogenesis and angiogenesis, suggest-
ing they could be relevant in treating metastatic PCa in-
cluding patients with SREs. Further studies should be
addressed on the effects of selinexor on bone calcification
in controls (tumor-free) mice in the short and long term
observation. This could help to define the role of XPO1 on
the osteoclastogenesis and of SINEs on prevention of
osteoclastogenesis in normal bone, but this is not the topic
of the present report. Selinexor, given orally, is now in
Phase 1 clinical trials in patients with advanced solid tu-
mors including patients with advanced PCa (clinicaltrailas.
gov:NCT01607905).
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